Literature DB >> 16170568

Homozygosity for the p.K136E mutation in the SLC17A5 gene as cause of an Italian severe Salla disease.

R Biancheri1, A Rossi, H A Verbeek, R Schot, F Corsolini, S Assereto, G M S Mancini, F W Verheijen, C Minetti, M Filocamo.   

Abstract

Lysosomal free sialic acid storage diseases are recessively inherited allelic neurodegenerative disorders that include Salla disease (SD) and infantile sialic acid storage disease (ISSD) caused by mutations in the SLC17A5 gene encoding for a lysosomal membrane protein, sialin, transporting sialic acid from lysosomes. The classical form of SD, enriched in the Finnish population, is related to the p.R39C designed Salla(FIN) founder mutation. A more severe phenotype is due both to compound heterozygosity for the p.R39C mutation and to different mutations. The p.R39C has not been reported in ISSD. We identified the first case of SD caused by the homozygosity for p.K136E (c.406A>G) mutation, showing a severe clinical picture, as demonstrated by the early age at onset, the degree of motor retardation, the occurrence of peripheral nerve involvement, as well as cerebral hypomyelination. Recently, in vitro functional studies have shown that the p.K136E mutant produces a mislocalization and a reduced activity of the intracellular sialin. We discuss the in vivo phenotypic consequence of the p.K136E in relation to the results obtained by the in vitro functional characterization of the p.K136E mutant. The severity of the clinical picture, in comparison with the classical SD, may be explained by the fact that the p.K136E mutation mislocalizes the protein to a greater degree than p.R39C. On the other hand, the presence of a residual transport activity may account for the absence of hepatosplenomegaly, dysostosis multiplex, and early lethality typical of ISSD and related to the abolished transport activity found in this latter form.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170568     DOI: 10.1007/s10048-005-0011-3

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  20 in total

1.  Cerebellar white matter involvement in Salla disease.

Authors:  Roberta Biancheri; A Rossi; M G Mancini; C Minetti
Journal:  Neuroradiology       Date:  2004-06-04       Impact factor: 2.804

2.  Brain involvement in Salla disease.

Authors:  P Sonninen; T Autti; T Varho; M Hämäläinen; R Raininko
Journal:  AJNR Am J Neuroradiol       Date:  1999-03       Impact factor: 3.825

3.  Clinical, morphological, and molecular aspects of sialic acid storage disease manifesting in utero.

Authors:  R Froissart; D Cheillan; R Bouvier; S Tourret; V Bonnet; M Piraud; I Maire
Journal:  J Med Genet       Date:  2005-04-01       Impact factor: 6.318

4.  Phenotypic spectrum of Salla disease, a free sialic acid storage disorder.

Authors:  Tarja T Varho; Liisa E Alajoki; Kristiina M Posti; Tapio T Korhonen; Martin G Renlund; Samuel R G Nyman; Matti L Sillanpää; Pertti P Aula
Journal:  Pediatr Neurol       Date:  2002-04       Impact factor: 3.372

5.  Central and peripheral nervous system dysfunction in the clinical variation of Salla disease.

Authors:  T Varho; S Jääskeläinen; U Tolonen; P Sonninen; L Vainionpää; P Aula; M Sillanpää
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

6.  Neurocognitive profiles in Salla disease.

Authors:  Liisa Alajoki; Tarja Varho; Kristiina Posti; Pertti Aula; Tapio Korhonen
Journal:  Dev Med Child Neurol       Date:  2004-12       Impact factor: 5.449

7.  Functional characterization of wild-type and mutant human sialin.

Authors:  Pierre Morin; Corinne Sagné; Bruno Gasnier
Journal:  EMBO J       Date:  2004-10-28       Impact factor: 11.598

8.  An Italian severe Salla disease variant associated with a SLC17A5 mutation earlier described in infantile sialic acid storage disease.

Authors:  R Biancheri; E Verbeek; A Rossi; R Gaggero; L Roccatagliata; R Gatti; Op van Diggelen; F W Verheijen; G M S Mancini
Journal:  Clin Genet       Date:  2002-06       Impact factor: 4.438

9.  Salla disease variant in a Dutch patient. Potential value of polymorphonuclear leucocytes for heterozygote detection.

Authors:  G M Mancini; P Hu; F W Verheijen; O P van Diggelen; H C Janse; W J Kleijer; F A Beemer; F G Jennekens
Journal:  Eur J Pediatr       Date:  1992-08       Impact factor: 3.183

Review 10.  Sialic acid storage disorders: observations on clinical and biochemical variation.

Authors:  G M Mancini; F W Verheijen; C E Beerens; M Renlund; P Aula
Journal:  Dev Neurosci       Date:  1991       Impact factor: 2.984

View more
  4 in total

Review 1.  Molecular physiology and pathophysiology of lysosomal membrane transporters.

Authors:  C Sagné; B Gasnier
Journal:  J Inherit Metab Dis       Date:  2008-04-15       Impact factor: 4.982

2.  Infantile Sialic Acid Storage Disease: Two Unrelated Inuit Cases Homozygous for a Common Novel SLC17A5 Mutation.

Authors:  Matthew A Lines; C Anthony Rupar; Jack W Rip; Berivan Baskin; Peter N Ray; Robert A Hegele; David Grynspan; Jean Michaud; Michael T Geraghty
Journal:  JIMD Rep       Date:  2013-07-31

3.  Free sialic acid storage disease without sialuria.

Authors:  Fanny Mochel; Bingzhi Yang; Julie Barritault; Jerry N Thompson; Udo F H Engelke; Nathan H McNeill; William S Benko; Christine R Kaneski; David R Adams; Maria Tsokos; Mones Abu-Asab; Marjan Huizing; Francois Seguin; Ron A Wevers; Jiahuan Ding; Frans W Verheijen; Raphael Schiffmann
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

4.  Identification of a large intronic transposal insertion in SLC17A5 causing sialic acid storage disease.

Authors:  Maja Tarailo-Graovac; Britt I Drögemöller; Wyeth W Wasserman; Colin J D Ross; Ans M W van den Ouweland; Niklas Darin; Gittan Kollberg; Clara D M van Karnebeek; Maria Blomqvist
Journal:  Orphanet J Rare Dis       Date:  2017-02-10       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.